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COMMENTARY
MEDICINE AND LAW
Ensuring Effective Pain Treatment
A National and Global Perspective
Allyn L. Taylor, JD, LLM, JSD
Lawrence O. Gostin, JD
Katrina A. Pagonis, JD, MPH, LLM
MEDICALAVAILABILITYOFEFFECTIVEPAINMEDICA-tion is vitally important domestically and glob-ally. Medical advances have substantially im-provedthetechnicalcapacity tocontrolpainand
diminishitsconsequences.Worldwide,millionsofpersonswith
chronic, acute, and terminal conditionshave foundrelief from
excruciatingpainthroughmedicalintervention.However,richer
countrieshavedisproportionatelybenefitedfromimprovements
in access to anduseof painmedication.The tragedy is that for
most of theworld’s population, particularlypersons inpoorer
countries, effective pain control is entirely unavailable.
An estimated 80% of persons worldwide do not receive
adequate treatment for pain, and severe undertreatment for
pain is an acute problem in more than 150 countries.1 Hos-
pice and palliative care services exist or are being devel-
oped in about 100 countries, but their global distribution
is uneven. Although the majority of the world’s population
lives inAsia andAfrica, only approximately 6%of theworld’s
palliative care services are located in these continents.2
Access to pain medication is distributed unevenly among
rich and poor nations and between their rich and poor popu-
lations.Domestically and globally, the burdenof poorlyman-
agedpain is disproportionately borne by themost vulnerable:
the poor, children, the elderly, individuals with a history of
substanceabuse, thementally ill,women,minorities,andpeople
of color.3 Thus, although the problem of undertreated and
untreated pain is most acute in the developing world, it also
affects the poor living in many industrialized nations.
In theUnited States, disparities inmanagement of chronic
and acute pain—including postoperative pain, cancer pain,
back pain, and migraine pain—have been documented in
health settings ranging fromemergencydepartments4 to nurs-
ing homes.3 A quarter or more of nursing home residents
reporting pain receive no analgesic medication.3,5
The lackofpainmanagementoptions formarginalizedpopu-
lations among and within countries raises significant global
health equity concerns. Equitable access to management re-
quires an appreciation of the multiple barriers that exist, na-
tionally and internationally, to providing effective analgesics
to patients. Complex socioeconomic, cultural, and political
factors merge in poor states and in some rich states to gener-
ate substandard painmanagement.Obstacles to effective pain
management can be grouped into 3 categories: attitudes and
misconceptions amonghealth careworkers and patients, lack
of access to common effective analgesics, and the legal and
regulatory environment.
Attitudinal Barriers
Attitudinalbarriers toadequate treatment forpain includepoor
understandingofandlackofeducationregardingpainandpain
medications. In rich and poor countries alike, many patients
and physicians hold unsubstantiated fears that addictionwill
result fromopioiduseduringappropriatepainmanagement.1,6
Research, however, has established that the risks of addiction
associatedwith theproperuseofmedicinalopioidsaregreatly
exaggerated and are very low in cases of acute, cancer, or ter-
minal pain.1,6Misconceptions amonghealthprofessionals are
perpetuated by a lack of appropriate training in painmanage-
ment.7,8 This problem is particularly acute in poor countries,
where a lack of training and basic education in the use of opi-
oid analgesics is widespread.
Poor education in pain management may also contribute
to socioeconomic, racial, and ethnic disparities in pain ame-
lioration. Clinical decision making about pain is inconsis-
tent, reflecting gaps in knowledge and training. Assessment
and treatment, therefore, is “vulnerable to social context ef-
fects” rather than sound scientific and clinical judgment.8,9
The ramifications of attitudinal factors is evident in coun-
tries such as Japan, where the annual per capita consump-
tion of oralmorphine is only 4.7mg—below the globalmean
of 5.9 mg.10 The relatively low level of analgesic consump-
tion is notable given Japan’s aging population, universal
health care system, affluence, and relative lack of extensive
regulatory restrictions on prescription narcotics.11
Access Barriers
Like attitudinal barriers, access barriers are particularly se-
vere in poorer countries, where the supply of narcoticmedi-
cations is inadequate.12 Even where narcotic analgesics are
available at the country level, physical access is often lim-
ited. Opioid availability in developing countries is often
See also p 70.
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restricted to specialty centers, depriving significant por-
tions of the population of access to such analgesics.13
Problems of physical access to narcotic analgesics contrib-
ute to the undertreatment of pain, especially amongminority
populations, intheUnitedStatesandother industrializedcoun-
tries.Pharmacies inpredominantlyminorityUSneighborhoods
are less likely tocarryopioidanalgesics incomparison to those
in predominantly white neighborhoods.14,15 In Michigan, for
example,pharmacies inzipcodeareaswithpredominantlymi-
noritygrouppopulationswere52 times less likely tocarry suf-
ficientsuppliesofopioidanalgesics thanthose inzipcodeareas
withpredominantlywhitepopulations.14InNewYorkCity,phar-
macies in predominantly nonwhite neighborhoods were ap-
proximately two-thirds less likely thanthose inpredominantly
white neighborhoods to carry sufficient supplies.15
Legal Barriers
Theoverregulationofmedicinalopiumis anenduringandcriti-
cal problem that contributes to the global undertreatment of
pain.16 Governments are legitimately concerned about the di-
versionof licitmedicines into illicitmarkets. Frequently, how-
ever, the regulatory responses have not been narrowly de-
signed to ensure that lawenforcement concerns donot unduly
interfere with medical availability.17 As a result, the prescrip-
tion anddistributionof opioids are so tightly regulated inmany
countries that the effective treatment of pain becomes bur-
densome for physicians, nurses, and pharmacists. At the pa-
tient level, overregulation stigmatizes the use of controlled an-
algesics and generates privacy concerns, further reducing the
treatment of pain.18
The national legal and regulatory environment contrib-
utes to the significant undertreatment of pain. Where regu-
lations controlling the manufacturing, importing, transport-
ing, and dispensing of narcotic analgesics are overly zealous
or poorly crafted, they contribute to the inadequate availabil-
ity of analgesics. Conversely, when national or subnational
regulations are reformed in an evidence-based manner, ac-
cess markedly improves. Kerala, India, for example, recently
loosenedonerous licensing requirements forpharmacies,which
facilitated amajor increase in community-basedpalliative care
centerswithoralmorphine and improvedpatient access.Care-
fully crafted regulations,moreover, can increase access to pain
medication without increasing misuse or causing increased
diversion to illicit markets.19
In some countries, regulations directly restrict the capac-
ity of health care professionals to appropriately treat pain.
For example, Argentina, Costa Rica, and Peru have adopted
laws and regulations limiting the dosage, the duration, or
both, of treatments involving opioids.12 Elsewhere, laws al-
low opioid prescriptions for some populations (eg, adults)
or some types of pain (eg, postoperative pain) but do not
allow opioid prescriptions for other populations (eg, chil-
dren) or other types of pain (eg, cancer pain).7
Fears of criminal prosecution also contribute to the under-
treatment of pain.While criminal prosecutions of physicians
arerare,recent,widelypublicizedcasesintheUnitedStateshave
hadachillingeffecton the treatmentofpain.7Elsewhere in the
world, criminal law creates fears of prosecution among phy-
sicians, nurses, pharmacists, and patients, constituting a sub-
stantial barrier to themedically appropriate treatmentofpain.
The international legal environment also contributes to
the undertreatment of pain. Morphine and other opioid an-
algesics that are integral to the relief of pain are controlled
substances under the 1961 United Nations Single Conven-
tion onNarcoticDrugs,20 the centerpiece of a complexUnited
Nations drug-regulatory regime. The Single Convention has
been ratified by 184 countries21 and is highly influential in
standardizing national drug regulatory laws among parties
as well as nonparties to the treaty.
The dual aims of the Single Convention are to control the
use and trafficking of substances with abuse potential while
ensuring the availability of these drugs for scientific andmedi-
cal purposes. Under the treaty, controlled substances are sub-
ject to stringent national regulation and global monitoring at
each stage of the supply chain.Government authorization (li-
censing and state ownership) is mandatory for participation
in any phase of the narcotics trade, and each individual in-
ternational transaction requires an export or import license.
At the heart of the Single Convention’s drug control scheme
is a global “estimates” system, which is designed to limit the
total quantity of drugs,whether produced domestically or im-
ported, to that needed for medical and scientific purposes.
Despite the dual aims of control and medical access in the
convention’s language and structure, the international insti-
tutions that have collective responsibility to implement the
convention—namely, theCommissiononNarcoticDrugs, the
InternationalNarcoticsControlBoard, and theUnitedNations
Office on Drugs and Crime—have emphasized a strict drug
prohibitionist and law enforcement approach to treaty inter-
pretation and application in an effort to bolster global action
against drug abuse.
Thisstrictprohibitionistapproachhasbeenineffectiveincoun-
teringglobaldrug traffickingand isatoddswithcontemporary
public health practice, which focuses on reducing drug abuse
and its adverse consequences. Inaddition, as amatterof treaty
interpretation, the SingleConvention is appropriately under-
stoodasnotonlyencompassingefforts tocontrolabusebutalso
promotingefforts toguarantee legitimate access topainmedi-
cation for patients. By deviating from the principle of balance
underlying the Single Convention, global drug agencies have
relegatedconcernsofmedical availability tosecondaryconsid-
eration. This law enforcement approach has beenmirrored at
the state level. Althoughmost governments are familiar with
theSingleConvention’sdrug-control requirements, few focus
on the mandate to ensure medical availability.19
Unrelieved Pain in the Poorest Countries
While barriers to adequate pain treatment are similar fromone
country to another, these similarities should not mask pro-
found disparities between rich and poor nations. Attitudinal,
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access, and legal barriers to adequate pain treatment aremag-
nified inpoorcountries,wherepainmanagementoccurswithin
an environment of poverty andunderdevelopment. Basic pain
management in poor countries must compete for limited re-
sourceswith other primary health care services aswell aswith
other social concerns, such as food and education.22 At the
patient level, poverty, demography, and geography merge to
further obstruct access tomedicinal opium. Patientswho can-
not afford medication or who are unable to travel to pallia-
tive care centers are excluded from care.
Global disparities in pain treatment are not merely at-
tributable to the intensification of qualitatively similar bar-
riers but also result from amanufactured access barrier: high
price. Morphine sulfate is generally a low-cost and effec-
tive analgesic ideally suited for resource-poor nations—a
10-mg generic immediate-release tablet should not costmore
than 1 cent.2,7 Opioid costs in developing countries, how-
ever, often exceed those in developed nations.While a typi-
cal month’s supply of morphine sulfate tablets should cost
only from $1.80 to $5.40, the actual cost in many develop-
ing countries ranges between $60 and $180.7When the cost
of opioid therapies is calculated by per capita monthly in-
come, the economic barriers to pain treatment are evenmore
marked. In Argentina andMexico, amonth of opioid therapy
can be more than 200% the average monthly income.12
Undertreatment of Pain as a Public Health Issue
Undertreatment of pain is a widespread problemwith a dis-
parate effect on the world’s most vulnerable populations
among and within nations. Unless undertreatment of pain
is prioritized as a public health issue, it is likely that an in-
creasing proportion of the world’s population will live with
and die in unnecessary pain.
The undertreatment of pain is not an intractable prob-
lem. Successful interventions have beendocumented inmany
countries, including Italy, Romania, and parts of India, pro-
viding useful models for reform. New narcotics legislation
and regulations in Romania, for example, vastly simplify the
administrative process for obtaining medicinal opioids and
allow the prescription of strong opioids for patients with
severe pain, regardless of the underlying cause.23 Roma-
nianhealth officials,moreover, are engaged in education cam-
paigns designed to inform the public, health care profes-
sionals, regulators, and the police.19
Legal reforms at the national level can be complemented
by international action. The Single Convention establishes
powerful mechanisms for improvingmedical access to pain
medications. Notably, the International Narcotics Control
Board could use its annual reports to draw attention to ac-
cess issues at the national level and to encourage countries
to undertake needed legal reforms. The board also could in-
corporate a medicinal access focus more explicitly in its re-
views of individual states and make balanced recommen-
dations that facilitate effective pain treatment.
Interventions to improve the treatment of pain should be a
keypublichealthpriority.Theproblemofundertreatmentneed
not be a global issue of immense proportions; it can be ame-
liorated by proven interventions. Moreover, unlike many of
today’s narrow, disease-specific public health interventions,
promoting equitable access to appropriate painmedication can
be an effective horizontal strategy that improves quality of life
for all patients. As disease burdens shift in various countries,
painwill persist. However, there is amplemedical capacity to
treat pain. Justice requires that equitable access to effectivepain
treatment be secured domestically and globally.
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